Form 4: Edwards Lifesciences SVP, Corporate Controller, Andrew M. Dahl, Reports Changes in Beneficial Ownership

Andrew M. Dahl, SVP, Corporate Controller of Edwards Lifesciences, reports a disposition of 176 shares of common stock on February 22, 2025, at a price of $73.3 per share.

Summary

• On February 22, 2025, Andrew M. Dahl, SVP, Corporate Controller of Edwards Lifesciences Corp, reported a transaction involving the disposition of 176 shares of common stock.
• The shares were disposed of at a price of $73.3 per share.
• Following the transaction, Dahl directly owns 4,684.1255 shares of Edwards Lifesciences Corp common stock.
• The report also notes that it includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting a standard transaction. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a change in beneficial ownership by a company insider.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in insider ownership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Edwards Lifesciences, Dahl Andrew M, Corporate Controller, Equity Securities, Transaction